{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:56:57Z","timestamp":1740149817446,"version":"3.37.3"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s12288-019-01213-7","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T04:49:24Z","timestamp":1571806164000},"page":"447-457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Re-defining Prognosis of Hematological Malignancies by Dynamic Response Assessment Methods: Lessons Learnt in Chronic Myeloid Leukemia, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma and Multiple Myeloma"],"prefix":"10.1007","volume":"36","author":[{"given":"Arihant","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankur","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9495-9789","authenticated-orcid":false,"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"issue":"8","key":"1213_CR1","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/bmt.2015.113","volume":"50","author":"A El-Jawahri","year":"2015","unstructured":"El-Jawahri A, Traeger L, Kuzmuk K, Eusebio J, Vandusen H, Keenan T et al (2015) Prognostic understanding, quality of life and mood in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 50(8):1119\u20131124","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"1213_CR2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"J Sokal","year":"1984","unstructured":"Sokal J, Cox E, Baccarani M, Tura S, Gomez G, Robertson J et al (1984) Prognostic discrimination in chronic granulocytic leukemia. Blood 63(4):789\u2013799","journal-title":"Blood"},{"issue":"11","key":"1213_CR3","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al (1998) A new prognostic score for survival of patients with chronic Myeloid Leukemia treated with interferon alfa writing committee for the collaborative CML prognostic factors project group. JNCI J Natl Cancer Inst 90(11):850\u2013859","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"3","key":"1213_CR4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118(3):686\u2013692","journal-title":"Blood"},{"issue":"19","key":"1213_CR5","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1182\/blood-2011-10-388967","volume":"119","author":"E Jabbour","year":"2012","unstructured":"Jabbour E, Cortes J, Nazha A, O\u2019Brien S, Quintas-Cardama A, Pierce S et al (2012) EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood 119(19):4524\u20134526","journal-title":"Blood"},{"issue":"29","key":"1213_CR6","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2011.37.6962","volume":"29","author":"D Marin","year":"2011","unstructured":"Marin D, Ibrahim AR, Goldman JM (2011) European treatment and outcome study (EUTOS) Score for chronic Myeloid Leukemia still requires more confirmation. J Clin Oncol 29(29):3944\u20133945","journal-title":"J Clin Oncol"},{"issue":"3","key":"1213_CR7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/ejh.12356","volume":"93","author":"B Hu","year":"2014","unstructured":"Hu B, Savani BN (2014) Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Eur J Haematol 93(3):179\u2013186","journal-title":"Eur J Haematol"},{"issue":"1","key":"1213_CR8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","volume":"2017","author":"F-X Mahon","year":"2017","unstructured":"Mahon F-X (2017) Treatment-free remission in CML: who, how, and why? Hematology 2017(1):102\u2013109","journal-title":"Hematology"},{"issue":"20","key":"1213_CR9","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"issue":"24","key":"1213_CR10","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM-L (2016) Life expectancy of patients with chronic Myeloid Leukemia approaches the life expectancy of the general population. J Clin Oncol 34(24):2851\u20132857","journal-title":"J Clin Oncol"},{"issue":"6","key":"1213_CR11","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884","journal-title":"Blood"},{"issue":"11","key":"1213_CR12","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.6004\/jnccn.2013.0157","volume":"11","author":"S O\u2019Brien","year":"2013","unstructured":"O\u2019Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E et al (2013) Chronic Myelogenous Leukemia, version 1.2014. J Natl Compr Canc Netw. 11(11):1327\u20131340","journal-title":"J Natl Compr Canc Netw."},{"issue":"9","key":"1213_CR13","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G et al (2014) Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 123(9):1353\u20131360","journal-title":"Blood"},{"issue":"2","key":"1213_CR14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11899-017-0375-0","volume":"12","author":"P Harrington","year":"2017","unstructured":"Harrington P, Kizilors A, de Lavallade H (2017) The role of early molecular response in the management of chronic phase CML. Curr Hematol Malig Rep 12(2):79\u201384","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"1213_CR15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","volume":"124","author":"S Branford","year":"2014","unstructured":"Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA et al (2014) Prognosis for patients with CML and &\u2009<\u200910% BCR-ABL1 after 3\u00a0months of imatinib depends on the rate of BCR-ABL1 decline. Blood 124(4):511\u2013518","journal-title":"Blood"},{"issue":"15_suppl","key":"1213_CR16","doi-asserted-by":"crossref","first-page":"e18038","DOI":"10.1200\/jco.2015.33.15_suppl.e18038","volume":"33","author":"P Malhotra","year":"2015","unstructured":"Malhotra P, Chikkodi SV, Naseem S, Khadwal A, Prakash G, Kumari S et al (2015) CHR Velocity as a predictor of early molecular response in patients with chronic myeloid leukemia. J Clin Oncol 33(15_suppl):e18038","journal-title":"J Clin Oncol"},{"issue":"1","key":"1213_CR17","first-page":"170","volume":"3","author":"G Barnes","year":"2015","unstructured":"Barnes G (2015) Burden of tyrosine kinase inhibitor failure in patients with chronic Myeloid Leukemia. J Leuk 3(1):170","journal-title":"J Leuk"},{"issue":"5","key":"1213_CR18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2013-12-544015","volume":"124","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Lipton JH, Spector N, Cervantes F, Pasquini R, Clementino NCD et al (2014) Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood 124(5):729\u2013736","journal-title":"Blood"},{"issue":"1","key":"1213_CR19","first-page":"170","volume":"3","author":"G Barnes","year":"2015","unstructured":"Barnes G (2015) Burden of tyrosine kinase inhibitor failure in patients with chronic Myeloid Leukemia. J Leuk 3(1):170","journal-title":"J Leuk"},{"issue":"20","key":"1213_CR20","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C et al (2016) Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic Myeloid Leukemia patients trial. J Clin Oncol 34(20):2333\u20132340","journal-title":"J Clin Oncol"},{"issue":"5","key":"1213_CR21","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim D-W, Issaragrisil S et al (2016) Long-term benefits and risks of frontline nilotinib vs. imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30(5):1044\u20131054","journal-title":"Leukemia"},{"issue":"3","key":"1213_CR22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A et al (2017) Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic Myeloid Leukemia. J Clin Oncol 35(3):298\u2013305","journal-title":"J Clin Oncol"},{"issue":"4","key":"1213_CR23","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT et al (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122(4):515\u2013522","journal-title":"Blood"},{"key":"1213_CR24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2017.02.028","volume":"77","author":"L Campiotti","year":"2017","unstructured":"Campiotti L, Suter MB, Guasti L, Piazza R, Gambacorti-Passerini C, Grandi AM et al (2017) Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a\u00a0systematic review and a meta-analysis. Eur J Cancer 77:48\u201356","journal-title":"Eur J Cancer"},{"issue":"22","key":"1213_CR25","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood.V128.22.787.787","volume":"128","author":"F Mahon","year":"2016","unstructured":"Mahon F, Richter J, Guilhot J, Hjorth-Hansen H, Almeida A, Janssen JJWMJ et al (2016) Cessation of tyrosine kinase inhibitors treatment in chronic Myeloid Leukemia patients with deep molecular response: results of the Euro-Ski trial. Blood 128(22):787","journal-title":"Blood"},{"issue":"7","key":"1213_CR26","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","volume":"129","author":"D Rea","year":"2017","unstructured":"Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A et al (2017) Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood 129(7):846\u2013854","journal-title":"Blood"},{"issue":"12","key":"1213_CR27","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K et al (2015) Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1\u00a0year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2(12):e528\u2013e535","journal-title":"Lancet Haematol"},{"issue":"7","key":"1213_CR28","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, G\u00f3mez Casares MT et al (2017) Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia 31(7):1525\u20131531","journal-title":"Leukemia"},{"issue":"15_suppl","key":"1213_CR29","doi-asserted-by":"crossref","first-page":"7054","DOI":"10.1200\/JCO.2016.34.15_suppl.7054","volume":"34","author":"TP Hughes","year":"2016","unstructured":"Hughes TP, Boquimpani C, Kim D-W, Benyamini N, Clementino NCD, Shuvaev V et al (2016) Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): first results from the ENESTop study. J Clin Oncol 34(15_suppl):7054","journal-title":"J Clin Oncol"},{"issue":"22","key":"1213_CR30","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1002\/cncr.30885","volume":"123","author":"L Legros","year":"2017","unstructured":"Legros L, Nicolini FE, Etienne G, Rousselot P, Rea D, Giraudier S et al (2017) Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. Cancer 123(22):4403\u20134410","journal-title":"Cancer"},{"issue":"1","key":"1213_CR31","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1182\/asheducation-2016.1.316","volume":"2016","author":"PWM Johnson","year":"2016","unstructured":"Johnson PWM (2016) Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet? Hematology 2016(1):316\u2013322","journal-title":"Hematology"},{"issue":"23","key":"1213_CR32","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2014.58.9846","volume":"33","author":"C Mamot","year":"2015","unstructured":"Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C et al (2015) Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38\/07). J Clin Oncol 33(23):2523\u20132529","journal-title":"J Clin Oncol"},{"issue":"24","key":"1213_CR33","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","volume":"25","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M et al (2007) Early Interim 2-[18 F]Fluoro-2-Deoxy-d-Glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage hodgkin\u2019s lymphoma: a report from a joint italian-danish study. J Clin Oncol 25(24):3746\u20133752","journal-title":"J Clin Oncol"},{"issue":"3","key":"1213_CR34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.6004\/jnccn.2018.0013","volume":"16","author":"RT Hoppe","year":"2018","unstructured":"Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Armand P et al (2018) NCCN guidelines insights: hodgkin lymphoma, Version 1.2018. J Natl Compr Cancer Netw 16(3):245\u2013254","journal-title":"J Natl Compr Cancer Netw"},{"issue":"17","key":"1213_CR35","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P et al (2015) Results of a trial of PET-directed therapy for early-stage hodgkin\u2019s lymphoma. N Engl J Med 372(17):1598\u20131607","journal-title":"N Engl J Med"},{"issue":"12","key":"1213_CR36","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","volume":"32","author":"JMM Raemaekers","year":"2014","unstructured":"Raemaekers JMM, Andr\u00e9 MPE, Federico M, Girinsky T, Oumedaly R, Brusamolino E et al (2014) Omitting radiotherapy in early positron emission tomography-negative stage I\/II hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol 32(12):1188\u20131194","journal-title":"J Clin Oncol"},{"issue":"16","key":"1213_CR37","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"MPE Andr\u00e9","year":"2017","unstructured":"Andr\u00e9 MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M et al (2017) Early positron emission tomography response-adapted treatment in stage i and ii hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol 35(16):1786\u20131794","journal-title":"J Clin Oncol"},{"issue":"25","key":"1213_CR38","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, Foss\u00e5 A, Berkahn L, Carella A et al (2016) Adapted treatment guided by interim PET-CT scan in advanced hodgkin\u2019s lymphoma. N Engl J Med 374(25):2419\u20132429","journal-title":"N Engl J Med"},{"issue":"23","key":"1213_CR39","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.V126.23.577.577","volume":"126","author":"O Casasnovas","year":"2015","unstructured":"Casasnovas O, Brice P, Bouabdallah R, Salles GA, Stamatoullas A, Dupuis J et al (2015) Randomized phase III study comparing an early pet driven treatment de-escalation to a not pet-monitored strategy in patients with advanced stages hodgkin lymphoma: interim analysis of the AHL2011 Lysa study. Blood 126(23):577","journal-title":"Blood"},{"issue":"21","key":"1213_CR40","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1182\/blood.V124.21.4409.4409","volume":"124","author":"EJ Dann","year":"2014","unstructured":"Dann EJ, Bairey O, Bar-Shalom R, Sabbag E, Izak M, Korenberg A et al (2014) Tailored therapy in hodgkin lymphoma, based on predefined risk factors and early interim PET\/CT: Israeli H2 study. Blood 124(21):4409","journal-title":"Blood"},{"issue":"1","key":"1213_CR41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/asheducation-2016.1.331","volume":"2016","author":"C Moskowitz","year":"2016","unstructured":"Moskowitz C (2016) Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma. Hematology 2016(1):331\u2013338","journal-title":"Hematology"},{"issue":"11","key":"1213_CR42","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2011.04.011","volume":"17","author":"JP Smeltzer","year":"2011","unstructured":"Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN et al (2011) Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant 17(11):1646\u20131652","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9980","key":"1213_CR43","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH et al (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385(9980):1853\u20131862","journal-title":"Lancet"},{"issue":"12","key":"1213_CR44","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S et al (2010) Long-term outcome of patients in the LNH-985 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood 116(12):2040\u20132045","journal-title":"Blood"},{"issue":"1","key":"1213_CR45","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","volume":"2016","author":"B Coiffier","year":"2016","unstructured":"Coiffier B, Sarkozy C (2016) Diffuse large B-cell lymphoma: r-CHOP failure\u2013what to do? Hematology 2016(1):366\u2013378","journal-title":"Hematology"},{"issue":"6","key":"1213_CR46","first-page":"6715","volume":"14","author":"M Jiang","year":"2017","unstructured":"Jiang M, Chen P, Ruan X, Ye X, Pan Y, Zhang J et al (2017) Interim 18F-FDG PET\/CT improves the prognostic value of S-IPI, R-IPI and NCCN-IPI in patients with diffuse large B-cell lymphoma. Oncol Lett 14(6):6715\u20136723","journal-title":"Oncol Lett"},{"issue":"1","key":"1213_CR47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2967\/jnumed.109.067892","volume":"51","author":"M Weiler-Sagie","year":"2010","unstructured":"Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I et al (2010) 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 51(1):25\u201330","journal-title":"J Nucl Med"},{"issue":"23","key":"1213_CR48","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood.V126.23.1458.1458","volume":"126","author":"H Huang","year":"2015","unstructured":"Huang H, Lin J, Guo C, Li S, Hong H, Li X et al (2015) Predictive value of interim 18 f-FDG PET-CT scans on diffuse large B-cell lymphoma treated with R-CHOP: a prospective study. Blood 126(23):1458","journal-title":"Blood"},{"issue":"23","key":"1213_CR49","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood.V126.23.815.815","volume":"126","author":"MS Hertzberg","year":"2015","unstructured":"Hertzberg MS, Gandhi MK, Butcher B, Columbus R, Taper J, Trotman J et al (2015) Early treatment intensification with R-ICE chemotherapy followed by autologous stem cell transplantation (ASCT) using zevalin-beam for patients with poor risk diffuse large B-cell lymphoma (DLBCL) as identified by interim PET\/CT scan performed after four. Blood 126(23):815","journal-title":"Blood"},{"issue":"12","key":"1213_CR50","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.2967\/jnumed.114.145326","volume":"55","author":"R Carr","year":"2014","unstructured":"Carr R, Fanti S, Paez D, Cerci J, Gyorke T, Redondo F et al (2014) Prospective international cohort study demonstrates inability of interim pet to predict treatment failure in diffuse large B-Cell lymphoma. J Nucl Med 55(12):1936\u20131944","journal-title":"J Nucl Med"},{"issue":"9","key":"1213_CR51","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.3109\/10428194.2015.1007506","volume":"56","author":"SF Huntington","year":"2015","unstructured":"Huntington SF, Nasta SD, Schuster SJ, Doshi JA, Svoboda J (2015) Utility of interim and end-of-treatment fluorodeoxyglucose positron emission tomography\u2013computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma. Leuk Lymphoma 56(9):2579\u20132584","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1213_CR52","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00259-018-4103-3","volume":"46","author":"CN Burggraaff","year":"2019","unstructured":"Burggraaff CN, de Jong A, Hoekstra OS, Hoetjes NJ, Nievelstein RAJ, Jansma EP et al (2019) Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 46(1):65\u201379","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"23","key":"1213_CR53","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2014.58.9846","volume":"33","author":"C Mamot","year":"2015","unstructured":"Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C et al (2015) Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated With R-CHOP-14 (SAKK 38\/07). J Clin Oncol 33(23):2523\u20132529","journal-title":"J Clin Oncol"},{"issue":"2","key":"1213_CR54","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2011.38.2648","volume":"30","author":"V Safar","year":"2012","unstructured":"Safar V, Dupuis J, Itti E, Jardin F, Fruchart C, Bardet S et al (2012) Interim [18]Fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol 30(2):184\u2013190","journal-title":"J Clin Oncol"},{"issue":"5","key":"1213_CR55","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1080\/10428194.2017.1369065","volume":"59","author":"A Winter","year":"2018","unstructured":"Winter A, Rybicki L, Shah SN, Jagadeesh D, Gerds AT, Hamilton BK et al (2018) Prognostic value of pre-transplant PET\/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Leuk Lymphoma 59(5):1195\u20131201","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"1213_CR56","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al (2015) Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33(26):2863\u20132869","journal-title":"J Clin Oncol"},{"issue":"11","key":"1213_CR57","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ajh.24131","volume":"90","author":"N Majithia","year":"2015","unstructured":"Majithia N, Vincent Rajkumar S, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA et al (2015) Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Am J Hematol 90(11):981\u2013985","journal-title":"Am J Hematol"},{"issue":"8","key":"1213_CR58","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1080\/10428194.2017.1386304","volume":"59","author":"U Yanamandra","year":"2018","unstructured":"Yanamandra U, Kumar SK (2018) Minimal residual disease analysis in myeloma\u2014when, why and where. Leuk Lymphoma 59(8):1772\u20131784","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"1213_CR59","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","volume":"51","author":"O Landgren","year":"2016","unstructured":"Landgren O, Devlin S, Boulad M, Mailankody S (2016) Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transplant 51(12):1565\u20131568","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"1213_CR60","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346","journal-title":"Lancet Oncol"},{"issue":"7","key":"1213_CR61","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","volume":"33","author":"L Rasche","year":"2019","unstructured":"Rasche L, Alapat D, Kumar M, Gershner G, McDonald J, Wardell CP et al (2019) Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia 33(7):1713\u20131722","journal-title":"Leukemia"},{"issue":"5","key":"1213_CR62","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","volume":"12","author":"S Mailankody","year":"2015","unstructured":"Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M et al (2015) Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol 12(5):286\u2013295","journal-title":"Nat Rev Clin Oncol"},{"key":"1213_CR63","doi-asserted-by":"crossref","unstructured":"Gandolfi S, Prada CP, Richardson P, Paba-Prada C. How I treat the young patient with multiple myeloma. Blood First Ed Pap. 2018","DOI":"10.1182\/blood-2017-05-693606"},{"issue":"7","key":"1213_CR64","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","volume":"37","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S et al (2019) Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol 37(7):589\u2013597","journal-title":"J Clin Oncol"},{"issue":"30","key":"1213_CR65","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I et al (2015) Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol 33(30):3459\u20133466","journal-title":"J Clin Oncol"},{"issue":"1","key":"1213_CR66","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/asheducation-2018.1.88","volume":"2018","author":"TM Wildes","year":"2018","unstructured":"Wildes TM, Anderson KC (2018) Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist. Hematology 2018(1):88\u201396","journal-title":"Hematology"},{"issue":"16","key":"1213_CR67","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood-2009-02-163485","volume":"114","author":"JP Radich","year":"2009","unstructured":"Radich JP (2009) How I monitor residual disease in chronic myeloid leukemia. Blood 114(16):3376\u20133381","journal-title":"Blood"},{"issue":"8","key":"1213_CR68","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2009.25.4367","volume":"28","author":"JJ Cerci","year":"2010","unstructured":"Cerci JJ, Trindade E, Pracchia LF, Pitella FA, Linardi CCG, Soares J et al (2010) Cost effectiveness of positron emission tomography in patients with hodgkin\u2019s lymphoma in unconfirmed complete remission or partial remission after first-line therapy. J Clin Oncol 28(8):1415\u20131421","journal-title":"J Clin Oncol"},{"issue":"9","key":"1213_CR69","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.3109\/10428194.2015.1007506","volume":"56","author":"SF Huntington","year":"2015","unstructured":"Huntington SF, Nasta SD, Schuster SJ, Doshi JA, Svoboda J (2015) Utility of interim and end-of-treatment fluorodeoxyglucose positron emission tomography\u2013computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma. Leuk Lymphoma 56(9):2579\u20132584","journal-title":"Leuk Lymphoma"},{"key":"1213_CR70","doi-asserted-by":"crossref","unstructured":"Carlson JJ, Eckert B, Zimmerman M. Cost-effectiveness of next-generation sequencing minimal residual disease testing during maintenance treatment for multiple myeloma. Presented at: 2019 American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2019; Chicago, Illinois. Abstract E19529","DOI":"10.1200\/JCO.2019.37.15_suppl.e19529"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-019-01213-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12288-019-01213-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-019-01213-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T23:40:58Z","timestamp":1603237258000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12288-019-01213-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1213"],"URL":"https:\/\/doi.org\/10.1007\/s12288-019-01213-7","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"type":"print","value":"0971-4502"},{"type":"electronic","value":"0974-0449"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"assertion":[{"value":"20 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Authors have no conflict of interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors state that the study did not involve any patient or animal participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The article does not involve any study with participation of humans or animals by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}]}}